We welcome Dr. Sharadha Dayalan Naidu, who recently received her PhD from the University of Dundee in Scotland.
Sharadha arrived in Baltimore in late March to assume her position in what we anticipate will be an ongoing relationship with a US-based pharmaceutical company which is developing activators of the cytoprotective (Nrf2) pathway that we have worked on for many years now. She is examining promising new synthetic compounds, developed using plant defensive compounds as clues. Her expertise as a superbly trained molecular biologist brings new skills to the Center. We are already benefiting from her presence as the first Reata Visiting Scholar. This program complements the Kagome Visiting Scholar program which has, with help from a Japanese food company, already supported four Visiting Scholars at the Center.
Latest posts by Cullman Chemoprotection Center (see all)
- Exciting Recent Paper on Inflammation and Nrf2 - July 16, 2018
- Sulforaphane and Epilepsy - July 11, 2018
- New Study from Korea: Sulforaphane Has Positive Effects in a Mouse Model of Alzheimer’s Disease - July 5, 2018